Last 1,093 INR
Change Today -6.70 / -0.61%
Volume 26.1K
CDH On Other Exchanges
Symbol
Exchange
Natl India
As of 4:38 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

cadila healthcare ltd (CDH) Snapshot

Open
1,095
Previous Close
1,100
Day High
1,112
Day Low
1,086
52 Week High
07/8/14 - 1,190
52 Week Low
08/20/13 - 629.00
Market Cap
223.8B
Average Volume 10 Days
83.9K
EPS TTM
39.25
Shares Outstanding
204.7M
EX-Date
07/17/14
P/E TM
27.8x
Dividend
9.00
Dividend Yield
0.82%
Current Stock Chart for CADILA HEALTHCARE LTD (CDH)

Related News

No related news articles were found.

cadila healthcare ltd (CDH) Related Businessweek News

No Related Businessweek News Found

cadila healthcare ltd (CDH) Details

Cadila Healthcare Limited discovers, develops, manufactures, and markets a range of healthcare products worldwide. It provides its products in various forms, including formulations, injectable, aerosols, ointments, vaccines, biologics, active pharmaceutical ingredients, etc. The company offers products in the areas of cardiovascular, gastro intestinal, respiratory, women’s healthcare, pain management, CNS, anti-infective, oncology, neuroscience, dermatology, nephrology, and chronic/lifestyle primarily under the Aten, Ocid, Deriphyllin, Pantodac, Atorva, Nucoxia, and Mifegest brands. It also provides consumer healthcare and wellness products, such as Sugar Free Gold, a sweetener; Sugar Free Natura, a sucralose based sugar substitute; Sugar Free D’lite, a healthy drink; Nutralite, a cholesterol-free table spread; and Actilife, a nutritional milk additive for adults, as well as skincare products comprising scrubs, peel-off, face wash, and soaps under its Everyuth and Dermacare brands. In addition, the company researches and develops a pipeline of 19 biologics comprising 17 biosimilars and 2 novel biological products; new drugs in cardio-metabolic, inflammation, pain, and oncology therapeutic areas; novel drug delivery systems; molecules for DMF filing and NPD molecules; and generic products, as well as solid orals, pulmonary, parenterals, suppository, topical, and oncology products. Further, it provides animal healthcare products comprising drugs, feed supplements, and vaccines for livestock, companion animals, and poultry. Additionally, the company develops vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, and HPV. It has strategic out-licensing deal with Abbott Laboratories for the commercial supply of products. The company was founded in 1952 and is headquartered in Ahmedabad, India.

Founded in 1952

cadila healthcare ltd (CDH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cadila healthcare ltd (CDH) Key Developments

Zydus Announces Data Presentations on ZYDPLAI, Once-Weekly Small Molecule DPP-IV Inhibitor for Treating Diabetes

The Zydus group will be presenting data on its molecule ZYDPLAI a novel compound in the Gliptin class of antidiabetic agents during the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 to be held from June 21-24, 2014 in Chicago, Illinois. ZYDPLA 1, currently in Phase 1 clinical evaluation in USA, is an orally active, small molecule NCE, discovered and developed by the Zydus Research Centre. ZYDPLA 1 works by blocking the enzyme Dipeptidyl Peptidase-4 (DPP-4), which inactivates the Incretin hormone GLP-1. By increasing the GLP-l levels, ZYDPLA I glucose-dependently increases insulin secretion. This results in an overall improvement in the glucose homoeostasis, including reduction in HbA 1c and blood sugar levels.

Cadila Healthcare Limited Announces Audited Consolidated and Company Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2014

Cadila Healthcare Limited announced audited consolidated and company earnings results for the fourth quarter and full year ended March 31, 2014. For the quarter, on consolidated basis, the company reported income from operations of INR 10,047.8 million against INR 8,115.3 million a year ago. Total income from operations was INR 11,015.4 million against INR 9,911.2 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 2,427.0 million compared to INR 2,368.8 million a year ago. Profit from ordinary activities before tax was INR 2,530.4 million compared to INR 2,303.4 million a year ago. Net profit from ordinary activities after tax was INR 2,166.8 million or INR 10.58 per basic and diluted share before and after extraordinary items compared to INR 2,207.4 million or INR 10.78 per basic and diluted share before and after extraordinary items a year ago. For the year, on consolidated basis, the company reported income from operations of INR 10,047.8 million against INR 29,781.1 million a year ago. Total income from operations was INR 40,421.1 million against INR 35,274.5 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 6,795.9 million compared to INR 5,894.6 million a year ago. Profit from ordinary activities before tax was INR 9,456.7 million compared to INR 5,313.6 million a year ago. Net profit from ordinary activities after tax was INR 9,035.9 million or INR 44.13 per basic and diluted share before and after extraordinary items compared to INR 4,985.5 million or INR 24.35 per basic and diluted share before and after extraordinary items a year ago. For the quarter, on standalone basis, the company reported income from operations of INR 19,519.8 million against INR 15,993.1 million a year ago. Total income from operations was INR 19,685.0 million against INR 16,116.0 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 3,057.7 million compared to INR 2,387.9 million a year ago. Profit from ordinary activities before tax was INR 2,811.8 million compared to INR 2,159.3 million a year ago. Net profit from ordinary activities after tax was INR 2,464.2 million or INR 11.68 per basic and diluted share before and after extraordinary items compared to INR 2,749.5 million or INR 12.80 per basic and diluted share before and after extraordinary items a year ago. For the year, on standalone basis, the company reported income from operations of INR 72,083.4 million against INR 62,848.4 million a year ago. Total income from operations was INR 72,240.3 million against INR 63,577.7 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 9,989.1 million compared to INR 9,403.2 million a year ago. Profit from ordinary activities before tax was INR 9,422.4 million compared to INR 8,086.6 million a year ago. Net profit from ordinary activities after tax was INR 8,362.3 million or INR 39.25 per basic and diluted share before and after extraordinary items compared to INR 6,898.9 million or INR 31.92 per basic and diluted share before and after extraordinary items a year ago.

Cadila Healthcare Limited Recommends Dividend for the Year Ended March 31, 2014; Incorporates Zydus Worldwide DMCC as Wholly Subsidiary in Dubai

Cadila Healthcare Limited's board of directors have recommended a dividend of INR 9.00 per equity shares that is 180% on 204,748,520 equity shares of INR 5.00 each for the financial year ended March 31, 2014. The company has incorporated Zydus Worldwide DMCC as a wholly subsidiary in Dubai on April 21, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDH:IN 1,093.30 INR -6.70

CDH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 442.70 INR +1.45
Ipca Laboratories Ltd 840.70 INR -8.85
Piramal Enterprises Ltd 629.10 INR -1.95
Ranbaxy Laboratories Ltd 559.00 INR -4.25
Torrent Pharmaceuticals Ltd 693.00 INR -3.95
View Industry Companies
 

Industry Analysis

CDH

Industry Average

Valuation CDH Industry Range
Price/Earnings 27.8x
Price/Sales 3.1x
Price/Book 6.5x
Price/Cash Flow 22.3x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CADILA HEALTHCARE LTD, please visit www.zyduscadila.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.